Media ReleasesSienna Cancer Diagnostics

View All Sienna Cancer Diagnostics News


Sienna Cancer Diagnostics, Sienna Secures $1.7M from Placement


Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative IVD tests, is pleased to announce the successful completion of a share placement to institutional and sophisticated investors. The Company received $1,657,185.74. A total of 47,348,164 ordinary shares were issued today at a price of 3.5 cents per share, with 18,442,647 shares issued under ASX listing rule 7.1 and 28,905,517 shares issued under ASX listing rule 7.1A. 

For more information, download the attached PDF.

Download this document